Considerations for controlling invasive meningococcal disease in high income countries

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Holst, Johan ^a   Nøkleby, Hanne ^a   Bettinger, Julie A ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Invasive meningococcal disease; Outer membrane vesicle vaccines; Serogroup b; Vaccine safety

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE;

ANAPHYLACTOID PURPURA; ARTICLE; BRONCHIOLITIS; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL (TOPIC); DEMYELINATING DISEASE; DISEASE SURVEILLANCE; DRUG SAFETY; EPIDEMIC; FEBRILE CONVULSION; FEVER; HEADACHE; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTIOUS MONONUCLEOSIS; INFLAMMATORY DISEASE; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INVASIVE MENINGOCOCCAL DISEASE; INVASIVE MENINGOCOCCCAL DISEASE; IRRITABILITY; MENINGOCOCCOSIS; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT;

DEVELOPED COUNTRIES; HUMANS; MENINGITIS, BACTERIAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PRODUCT SURVEILLANCE, POSTMARKETING; SENTINEL SURVEILLANCE; SEPSIS;

EID: 84861118340     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.093     Document Type: Article

References (84)

1. Recommendations of the International Task Force for Disease Eradication (updated April 2008). MMWR 1993, 42(RR-16):8. CDC.
2. The World Bank Data: How we classify countries. ; 2010 [cited 2011 September 3, 2011]. http://data.worldbank.org/about/country-classifications.
3. Sáfadi M.A., McIntosh E.D. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Rev Vaccines 2011, 10:1717-1730.
4. Pace D. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev Vaccines 2009, 8:529-542.
5. Pace D., Pollard A.J., Messonier N.E. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009, 27(Suppl 2):B30-B41.
6. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl 2):B3-B12.
7. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010, 10:112-124.
8. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
9. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103:10834-10839.
10. Bettinger J.A., Scheifele D.W., Kellner J.D., Halperin S.A., Vaudry W., Law B., et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010, 28:2130-2136.
11. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 2007;56:1077-80.
12. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8.
13. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
14. Snape M.D., Pollard A.J. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005, 5:21-30.
15. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009, 28:220-224.
16. Swartley J.S., Marfin A.A., Edupuganti S., Liu L.J., Cieslak P., Perkins B., et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997, 94:271-276.
17. Vogel U., Claus H., Frosch M. Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 2000, 342:219-220.
18. Harrison L.H., Shutt K.A., Schmink S.E., Marsh J.W., Harcourt B.H., Wang X., et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era-United States, 2000-2005. J Infect Dis 2010, 201:1208-1224.
19. Taha M.K., Achtman M., Alonso J.M., Greenwood B., Ramsay M., Fox A., et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000, 356:2159.
20. Hahne S.J., Gray S.J., Jean F., Aguilera Crowcroft N.S., Nichols T., et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002, 359:582-583.
21. Mayer L.W., Reeves M.W., Al-Hamdan N., Sacchi C.T., Taha M.K., Ajello G.W., et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185:1596-1605.
22. Wilder-Smith A., Chow A., Goh K.T. Emergence and disappearance of W135 meningococcal disease. Epidemiol Infect 2010, 138:976-978.
23. Maiden M.C., Spratt B.G. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 1999, 354:615-616.
24. Trotter C.L., Ramsay M.E., Gray S., Fox A., Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006, 6:616-617. [author reply 7-8].
25. Vicente D., Esnal O., Lopez de Goicoechea M.J., Cisterna R., Perez-Trallero E. Influence of two vaccination campaigns on genetic diversity of invasive Neisseria meningitidis isolates in northern Spain (1997-2008). PLoS One 2009, 4:e8501.
26. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362:1511-1520.
27. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338:1093-1096.
28. Galloway Y., Stehr-Green P., McNicholas A., O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009, 38:413-418.
29. Sotolongo P.F., Huergo C.C., Gil V.C., Diaz E.M.F., Valdespino I.E.C., Gotera N.G. Cuban Meningococcal BC vaccine: experience and contribution from 20 years of application. MEDICC Rev 2007, 9:6.
30. Taha M.K., Zarantonelli M.L., Alonso J.M., Naess L.M., Holst J., Feiring B., et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007, 25:2537-2538.
31. Caron F., du Chatelet I.P., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11:455-463.
32. van der Ende A., Hopman C.T., Zaat S., Essink B.B., Berkhout B., Dankert J. Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the -10 and -35 regions of the promoter. J Bacteriol 1995, 177:2475-2480.
33. van der Ende A., Hopman C.T., Dankert J. Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis. Infect Immun 1999, 67:2928-2934.
34. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281:1520-1527.
35. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(Suppl 2):S54-S65.
36. Mascioni A., Bentley B.E., Camarda R., Dilts D.A., Fink P., Gusarova V., et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 2009, 284:8738-8746.
37. McNeil L.K., Murphy E., Zhao X.J., Guttmann S., Harris S.L., Scott A.A., et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009, 27:3417-3421.
38. Marshall H., Richmond P., Nissen M., Jiang Q., Jansen K., Garcés-Sanchez M., et al. Phase 2 randomised controlled clinical trial of safety and immunogenicity of a meningococcal b bivalent vaccine (rLP2086) in healthy adolescents. The 29th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), The Hague, The Netherlands, June 7-11, 2011 2011.
39. Bai X.F., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011, 11:969-985.
40. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177:501-510.
41. Comanducci M., Bambini S., Caugant D.A., Mora M., Brunelli B., Capecchi B., et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004, 72:4217-4223.
42. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010, 107:3770-3775.
43. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
44. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28:6086-6093.
45. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, 107:19490-19495.
46. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17:919-929.
47. Wang X., Cohn A., Comanducci M., Andrew L., Zhao X., MacNeil J.R., et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011, 29:4739-4744.
48. Findlow J., Lowe A., Deane S., Balmer P., van den Dobbelsteen G., Dawson M., et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine 2005, 23:2623-2627.
49. Miller D.L., Alderslade R., Ross E.M. Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol Rev 1982, 4:1-24.
50. Stewart G.T. Toxicity of pertussis vaccine. Lancet 1977, 2:1130.
51. Stewart G.T. Vaccination against whooping-cough. Efficacy versus risks. Lancet 1977, 1:234-237.
52. Cherry J.D. 'Pertussis vaccine encephalopathy': it is time to recognize it as the myth that it is. JAMA 1990, 263:1679-1680.
53. Morgan C.M., Blumberg D.A., Cherry J.D., Reisinger K.S., Blatter M.M., Blumer J.L., et al. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children. Am J Dis Child 1990, 144:41-45.
54. Rosenqvist E., Hoiby E.A., Bjune G., Aase A., Halstensen A., Lehmann A.K., et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev Biol Stand 1998, 92:323-333.
55. Oster P., O'Hallahan J., Aaberge I., Tilman S., Ypma E., Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007, 25:3075-3079.
56. Nokleby H., Aavitsland P., O'Hallahan J., Feiring B., Tilman S., Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007, 25:3080-3084.
57. Nokleby H., Feiring B. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH Ann 1991, 14:95-101. [discussion 101-2].
58. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
59. Santolaya M., O'Ryan M., Valenzuela M., Prado V., Vergara R., Muñoz A., et al. Immunogenicity and tolerability of an investigational multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents. The 29th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2011.
60. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51:1127-1137.
61. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29:e71-e79.
62. Toneatto D., Oster P., Deboer A.C., Emerson A., Santos G.F., Ypma E., et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccines 2011, 7:781-791.
63. Beeretz I., Snape M., Finn A., Heath P., Collinson, Bona G., et al. Reactogenicity and safety of multicomponent meningococcal serogroup B vaccine (4CMenB) administered with or without routine infant vaccinations in different schedules. The 29th annual meeting of the European Society for Paediatric Infectious Disease 2011.
64. Esposito S., Vesikari T., Kimura A., Ypma E., Toneatto D., Dull P. Tolerability of a three-dose schedule of an investigational, multicomponent, meningococcal sergroup B vaccine and routine infant vaccines in a lot consistency trial. 17th international pathogenic Neisseria conference, Banff, Canada, September 11-16, 2010 2010.
65. McNicholas A., Galloway Y., Stehr-Green P., Reid S., Radke S., Sexton K., et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Hum Vaccines 2007, 3:196-204.
66. Stehr-Green P., Radke S., Kieft C., Galloway Y., McNicholas A., Reid S. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand. Vaccine 2008, 26:739-742.
67. Tatley M.V., Kunac D.L., McNicholas A., Zhou L., Ballantyne S., Ashton J., et al. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand. Vaccine 2008, 26:2746-2752.
68. Folb P.I., Bernatowska E., Chen R., Clemens J., Dodoo A.N., Ellenberg S.S., et al. A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety. Am J Public Health 2004, 94:1926-1931.
69. Anonymous Global Advisory Committee on Vaccine Safety, 12-13 December 2007. WER 2008, 83:7.
70. Stehr-Green P., Galloway Y., Kieft C., McNicholas A. The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand. N Z Med J 2007, 120:1-7. http://journal.nzma.org.nz/journal/120-1263/2746/.
71. Sexton K., McNicholas A., Galloway Y., Radke S., Kieft C., Stehr-Green P., et al. Henoch-Schonlein purpura and meningococcal B vaccination. Arch Dis Child 2009, 94:224-226.
72. Nøkleby H. Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine. Expert Rev Vaccines 2007, 6:863-869.
73. Magnus P., Brubakk O., Nyland H., Wold B.H., Gjessing H.K., Brandt I., et al. Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome. Vaccine 2009, 27:23-27.
74. O'Hallahan J., Lennon D., Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 2004, 23(Suppl 12):S293-S298.
75. Kimura A., Toneatto D., Kleinschmidt A., Wang H., Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011, 18:483-486.
76. Ball R. Methods of ensuring vaccine safety. Expert Rev Vaccines 2002, 1:161-168.
77. Miller E., Andrews N., Stowe J., Grant A., Waight P., Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol 2007, 165:704-709.
78. Iskander J.K., Miller E.R., Chen R.T. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann 2004, 33:599-606.
79. Kohl K.S., Bonhoeffer J., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Safety 2003, 12:335-340.
80. Dales L., Hammer S.J., Smith N.J. Time trends in autism and in MMR immunization coverage in California. JAMA 2001, 285:1183-1185.
81. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14:195-207. [discussion 208-10].
82. Kelly C., Arnold R., Galloway Y., O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166:817-823.
83. Arnold R., Galloway Y., McNicholas A., O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011, 29:7100-7106.
84. Alaszewski A., Horlick-Jones T. How can doctors communicate information about risk more effectively. BMJ 2003, 327:728-731.